BrainStorm Cell Therapeutics reported that its NurOwn stem-cell therapy for amyotrophic lateral sclerosis (ALS), also called Lou Gehrig’s disease, failed to demonstrate efficacy in a phase 3 study.

Although the treatment did not achieve the primary endpoint, it did generate a statistically significant increase of neurotrophic factors and a reduction in neurodegenerative and neuroinflammatory biomarkers, the company said.

Despite the mixed trial results, BrainStorm CEO Chaim Lebovits said the N.Y.-based drugmaker is still committed to pursuing FDA approval for NurOwn and is in ongoing talks with the agency.